β-Nicotinamide mononucleotide (Synonyms: βNMN) |
カタログ番号GC16971 |
β-ニコチンアミドモノヌクレオチドは、ニコチンアミドリン酸フォスホリボシルトランスフェラーゼ(NAMPT)反応の生成物であり、重要なNAD +中間体です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1094-61-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
Hepa1-6 cells |
Preparation Method |
β-Nicotinamide mononucleotide was added to the cell medium |
Reaction Conditions |
0.5-1 mMβ-Nicotinamide mononucleotide |
Applications |
Intracellular NAD + levels were significantly reduced by knocking down or knocking down Nampt or treated with the Nampt inhibitor FK866, whereas NAD + levels were significantly increased by supplementation with NAD + precursors NAM or β-Nicotinamide mononucleotide. |
Animal experiment [2]: | |
Animal models |
Nampt+/- female mice |
Preparation Method |
For GTTs, mice were injected with PBS or β-Nicotinamide mononucleotide (500 mg/kg body weight) and fasted for 14 hrs; dextrose (3 g/kg body weight) was then injected intraperitoneally. |
Dosage form |
500 mg/kg β-Nicotinamide mononucleotide for 0、15、30、60,120min |
Applications |
After β-Nicotinamide mononucleotide administration, there was no difference in blood glucose levels in GTTs between Nampt+/- and control female mice. In addition, β-Nicotinamide mononucleotide-treated Nampt+/- and control mice also had similar plasma insulin levels at each time point. β-Nicotinamide mononucleotide administration corrects the defect in GSIS observed in Nampt+/- mice. |
References: [1]: Lv H, Lv G, et,al. NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. Cell Metab. 2021 Jan 5;33(1):110-127.e5. doi: 10.1016/j.cmet.2020.10.021. Epub 2020 Nov 9. PMID: 33171124. |
β-ニコチンアミド一リン酸モノヌクレオチドは、ニコチンアミドフォスホリボシルトランスフェラーゼ(NAMPT)反応の生成物であり、重要なNAD +中間体です。 β-ニコチンアミド一リン酸モノヌクレオチドの薬理学的活性には、細胞生化学機能、心臓保護、糖尿病、アルツハイマー病、肥満に関連する合併症が含まれます[1]。
細胞内のNAD+レベルは、Namptをノックダウンしたり、Nampt阻害剤FK866で処理したりすることによって有意に低下しました。一方、NAD+前駆体のNAMまたはβ-ニコチンアミド一リン酸を補充することによって、NAD+レベルが有意に増加しました[3]。HEK293細胞へのβ-ニコチンアミド一リン酸(NAD+前駆体)の投与は、核内での塩基配列複製速度を向上させるために、線維芽細胞中で活性化されます。これは、粒子数が減少している代わりに核内で新しい塩基配列が生成されています[7]。
β-ニコチンアミドモノヌクレオチドの投与後、Nampt+/-と対照群の雌マウスにおいてGTT中の血糖値に差は見られませんでした。さらに、β-ニコチンアミドモノヌクレオチドを投与されたNampt+/-と対照群のマウスは、各時間点で同様の血漿インスリン値を示しました。β-ニコチンアミドモノヌクレオチド投与により、Nampt+/-マウスで観察されたGSISの欠陥が修正されます[2]。 β-ニコチンアミド モ ノ ヌ クレオ チッド は HFD 誘導性 T2D マウス における NAD + 水準 の回復によってグルコース不耐性を改善します。また、SIRT1 の活性化を介して一部酸化ストレス、炎症反応、循環リズム関連遺伝子発現も回復します[4]。臨床的な低用量分割投与法で誘導されたマウス模型では、NAD + 前駆体補充により mtDNA 減少と心機能障害を防止できました[5]。全身動物実験において、β-ニコチンアミドモノヌクレオチドがNAD + 前駆体としてニコチンアミド(Nam)よりも優れているかどうか調べた結果、β-ニコチンアミド モ ノ ヌ クレオ チッド は Nam よりも体内に長く留まることがわかりました[6]。
References:
[1]: Poddar SK, Sifat AE, et,al. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules. 2019 Jan 21;9(1):34. doi: 10.3390/biom9010034. PMID: 30669679; PMCID: PMC6359187.
[2]: Revollo JR, KÖrner A, et,al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007 Nov;6(5):363-75. doi: 10.1016/j.cmet.2007.09.003. PMID: 17983582; PMCID: PMC2098698.
[3]: Lv H, Lv G, et,al. NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. Cell Metab. 2021 Jan 5;33(1):110-127.e5. doi: 10.1016/j.cmet.2020.10.021. Epub 2020 Nov 9. PMID: 33171124.
[4]:Yoshino J, Mills KF, et,al. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011 Oct 5;14(4):528-36. doi: 10.1016/j.cmet.2011.08.014. PMID: 21982712; PMCID: PMC3204926.
[5]: Li J, Wang PY, et,al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19626-19634. doi: 10.1073/pnas.1904979116. Epub 2019 Sep 5. PMID: 31488712; PMCID: PMC6765288.
[6]: Kawamura T, Mori N, et,al. β-Nicotinamide Mononucleotide, an Anti-Aging Candidate Compound, Is Retained in the Body for Longer than Nicotinamide in Rats. J Nutr Sci Vitaminol (Tokyo). 2016;62(4):272-276. doi: 10.3177/jnsv.62.272. PMID: 27725413.
[7]:Cros C, Margier M, et,al. Nicotinamide Mononucleotide Administration Triggers Macrophages Reprogramming and Alleviates Inflammation During Sepsis Induced by Experimental Peritonitis. Front Mol Biosci. 2022 Jun 27;9:895028. doi: 10.3389/fmolb.2022.895028. PMID: 35832733; PMCID: PMC9271973.
Cas No. | 1094-61-7 | SDF | |
同義語 | βNMN | ||
Chemical Name | ((2R,3S,4R,5R)-3,4-dihydroxy-5-(3-(hydroxy(imino)methyl)pyridin-1-ium-1-yl)tetrahydrofuran-2-yl)methyl hydrogen phosphate | ||
Canonical SMILES | N=C(O)C1=C[N+]([C@@]2([H])[C@@](O)([H])[C@@](O)([H])[C@@](O2)([H])COP(O)([O-])=O)=CC=C1 | ||
Formula | C11H16N2O8P | M.Wt | 334.22 |
溶解度 | ≥ 33.4mg/mL in Water | Storage | 4°C, protect from light |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.992 mL | 14.9602 mL | 29.9204 mL |
5 mM | 0.5984 mL | 2.992 mL | 5.9841 mL |
10 mM | 0.2992 mL | 1.496 mL | 2.992 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 3 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *